Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037570 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
A Phase 2 study of Peptic Ulcer Hemorrhage, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT00037570: Completed Phase 2 study of Peptic Ulcer Hemorrhage, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00037570 is a Phase 2 study of Peptic Ulcer Hemorrhage that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037570, a Phase 2 study of Peptic Ulcer Hemorrhage, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
Conditions Studied
Interventions
- DRUG Pantoprazole
Study Locations (6)
California
- - Los Angeles
- - San Diego
Ohio
- - Cincinnati
Pennsylvania
- - Philadelphia
Texas
- - Houston
Virginia
- - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-11 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
What the finished NCT00037570 record still lists
NCT00037570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Peptic Ulcer Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Pantoprazole is the first listed.
NCT00037570 lists 6 locations in 5 states (California, Ohio, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00037570 about?
NCT00037570 is a clinical study titled "Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage". This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ...
What is the current status of trial NCT00037570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-11. Estimated completion is 2002-02.
What conditions does trial NCT00037570 study?
This clinical trial studies the following conditions: Peptic Ulcer Hemorrhage.
What interventions are being tested in trial NCT00037570?
The interventions under investigation include: Pantoprazole (DRUG).
Who is sponsoring clinical trial NCT00037570?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00037570 being conducted?
This trial has 6 study locations across California, Ohio, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peptic Ulcer Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00037570's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia